Bipolar I or bipolar II?

Somebody has told you it is "just bipolar II," or "the mild one," or "bipolar lite," and you have gone home to a depression that has lasted four months and a life you cannot get back on the road. The reassurance did not match the experience, and the research says the experience is right.

The short answer: the definitional difference is one thing only — whether you have ever had a manic episode. Bipolar I requires one; bipolar II requires hypomania plus at least one major depressive episode and no mania. That is the whole of it. What the difference is not is severity. In prospective follow-up, people with bipolar II were symptomatic 53.9 percent of weeks against 47.3 percent for bipolar I, and spent 50.3 percent of all weeks depressed against 31.9 percent. At equal depressive severity the two are equally impairing. Suicide attempt rates do not differ significantly, and a meta-analysis of completed suicide found a pooled odds ratio of 1.00. Bipolar II is a different illness, not a lesser one.¹ ² ³ ⁴ ⁵

The definitional line

The asymmetry is worth staring at. Bipolar I can be diagnosed without any history of depression at all; bipolar II cannot be diagnosed without it. Which is one reason bipolar II is the more depression-heavy illness by construction as well as in the data.

What the long follow-up found

Two prospective studies from the same programme, following people for more than a decade with weekly symptom ratings:¹ ²

People with bipolar II spent 58 percent more of their follow-up weeks depressed than people with bipolar I, and more of their weeks symptomatic overall. A related finding from the same cohort worth knowing if a clinician has queried whether your hypomanias are "long enough": patients with brief hypomanias of two to six days and those with hypomanias of seven days or more "were not significantly different on any measure."²

Is bipolar II less impairing?

No — at the same symptom severity.

The same investigators compared 158 people with bipolar I and 133 with bipolar II followed a mean of fifteen years, and reported: "At each level of depressive symptom severity, BP-I and BP-II are equally impairing." They also found that "Depressive symptoms are at least as disabling as manic or hypomanic symptoms at corresponding severity levels and, in some cases, significantly more so," and that "Subsyndromal hypomanic symptoms are not disabling in BP-II, and they may even enhance functioning."³

That last clause is the trap in miniature. The part of bipolar II that looks like the illness from outside is the part that is not disabling. The disability is in the depression, which is where the person spends half their life.

Is the suicide risk lower?

The evidence says no.

• Attempts. Across fifteen retrospective studies suitable for meta-analysis, "the prevalence of attempted suicide in BPII and BPI was not significantly different: 32.4% and 36.3%, respectively (OR = 1.21, 95% CI: 0.98-1.48, p = 0.07)."⁴
• Completed suicide. A meta-analysis comparing the two found "The pooled odds ratio of BD-II suicide rates to BD-I was 1.00 [95 % CI = 0.75, 1.34]," concluding that the study "underscores the severity of BD-II, with a risk for suicide not dissimilar from BD-I." The authors note the small number of studies and heterogeneity as limitations.⁵

The registry picture: different, not milder

The largest direct comparison — 4,806 people with bipolar I and 3,960 with bipolar II in a national quality register — found the two differ on many axes and that the differences run both ways:⁶

Where bipolar II is worse: higher rate of depressive episodes, more frequent suicide attempts. The authors' conclusion: the results "counter the notion that BDII is a milder form of BDI, but rather a more complex condition with regard to clinical course and comorbidity."⁶

Where bipolar I is worse: higher rate of hospitalisations and elated episodes, higher body mass index, and a higher rate of endocrine, nutritional and metabolic disease.⁶

And in an Italian sample, people with bipolar II had more favourable circumstances on paper — occupational stability, cohabitation, marital status — alongside "significantly longer duration of untreated illness" and more lifetime anxiety comorbidity.⁷ Doing better socially and being treated later are not in tension; they are the same phenomenon. A person who keeps working is a person nobody refers.

Why the label still matters clinically

Not for severity. For treatment.

• The elevated pole is what the medications are largely licensed around. Several drugs approved in the United States for bipolar depression carry a bipolar I indication specifically — lurasidone, cariprazine and the olanzapine–fluoxetine combination all say bipolar I in their labelling. Quetiapine is the exception whose bipolar-depression trials enrolled bipolar I or II.⁸
• The antidepressant question is answered differently by subtype. An international task force reported that "The frequency and severity of antidepressant-associated mood elevations appear to be greater in bipolar I than bipolar II disorder. Hence, in bipolar I patients antidepressants should be prescribed only as an adjunct to mood-stabilizing medications."⁹ The full antidepressant answer →
• The diagnosis is what gets you the illness-appropriate long-term plan rather than a series of trials of treatment for recurrent depression.

If you are trying to work out which one you have

The clinician's job, but you can help — and the thing they need is a history of the elevated pole, which is exactly what nobody remembers to report.

• Have you ever had four or more consecutive days of unusually elevated, expansive or irritable mood with more energy than usual, noticeable to other people? What did your sleep do? What did you start?
• Did it ever go further — a week or more, with marked impairment at work or in relationships, or psychosis, or a hospital admission? That is the line between the two.
• Ask someone who was there. The guidelines say to "encourage people to invite a family member or carer to give a corroborative history," and elevated mood is the symptom people are least able to report about themselves.¹⁰
• Do not settle it with an online questionnaire. The UK guideline is explicit: "Do not use questionnaires in primary care to identify bipolar disorder in adults."¹¹ In psychiatric outpatients, 15.2 percent of people who did not have bipolar disorder screened positive on the most widely used screener.¹²

Why the diagnosis takes so long, and what to bring → · The printable mood and sleep log →

Q&A

Q: What is the difference between bipolar I and bipolar II? A: Bipolar I requires at least one manic episode; bipolar II requires at least one hypomanic episode plus at least one major depressive episode, and no manic episode.¹ ² That single distinction is the whole definitional difference — it does not describe how ill, how impaired or how at risk a person is.

Q: Is bipolar II milder? A: Not on the measures that matter to a life. More weeks symptomatic, substantially more weeks depressed, equal impairment at equal depressive severity, and no significant difference in suicide attempts or in completed suicide.¹ ² ³ ⁴ ⁵

Q: Can bipolar II turn into bipolar I? A: One manic episode changes the diagnosis, and that does happen. In a study of young people followed for four years, 25 percent of those with bipolar II converted to bipolar I.¹³ It is a reclassification of history rather than a new disease.

Q: My hypomanias only last a couple of days. Does that count? A: The manuals set four days as the threshold. Empirically, people with brief hypomanias of two to six days and those with longer ones "were not significantly different on any measure" in the follow-up study.² Report the episodes exactly as they happened and let a clinician apply the criteria.

Q: I like my hypomanias. Do I have to treat them? A: That is a real and common position, and the finding that subsyndromal hypomanic symptoms may even improve functioning is not nothing.³ The counterweight is what tends to follow them, and what an untreated course costs over decades. Worth having as an explicit conversation with a prescriber rather than a silent one.

Q: Does it change the therapy I should get? A: Less than it changes the medication conversation. The psychosocial treatments with evidence — psychoeducation, family-focused therapy, rhythm-focused work — were tested across both. What the psychotherapies do →

Ready to get the assessment right? Filter therapists by approach, schedule and payment route → · The full bipolar map →

Sources

1. Judd LL, Akiskal HS, Schettler PJ, et al., "The long-term natural history of the weekly symptomatic status of bipolar I disorder," Archives of General Psychiatry 59(6), 2002, 530–537 — 146 patients, mean 12.8 years; symptomatic 47.3% of weeks, depressed 31.9%, manic or hypomanic 8.9%, cycling or mixed 5.9% — europepmc.org.
2. Judd LL, Akiskal HS, Schettler PJ, et al., "A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder," Archives of General Psychiatry 60(3), 2003, 261–269 — 86 patients, mean 13.4 years; symptomatic 53.9% of weeks, depressed 50.3%, hypomanic 1.3%; "Patients with BP-II of brief (2-6 days) vs longer (≥7 days) hypomanias were not significantly different on any measure" — europepmc.org.
3. Judd LL, Akiskal HS, Schettler PJ, et al., "Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study," Archives of General Psychiatry 62(12), 2005, 1322–1330 — 158 bipolar I and 133 bipolar II patients, mean 15 years; "At each level of depressive symptom severity, BP-I and BP-II are equally impairing"; "Depressive symptoms are at least as disabling as manic or hypomanic symptoms at corresponding severity levels"; "Subsyndromal hypomanic symptoms are not disabling in BP-II, and they may even enhance functioning" — doi.org.
4. Novick DM, Swartz HA, Frank E, "Suicide attempts in bipolar I and bipolar II disorder: a review and meta-analysis of the evidence," Bipolar Disorders 12(1), 2010, 1–9 — "In 15 retrospective studies suitable for meta-analysis, the prevalence of attempted suicide in BPII and BPI was not significantly different: 32.4% and 36.3%, respectively (OR = 1.21, 95% CI: 0.98-1.48, p = 0.07)" — pmc.ncbi.nlm.nih.gov.
5. Dev DA, Le GH, Kwan ATH, et al., "Comparing suicide completion rates in bipolar I versus bipolar II disorder: a systematic review and meta-analysis," Journal of Affective Disorders 361, 2024, 480–488 — "The pooled odds ratio of BD-II suicide rates to BD-I was 1.00 [95 % CI = 0.75, 1.34]"; "Our study underscores the severity of BD-II, with a risk for suicide not dissimilar from BD-I" — doi.org.
6. Karanti A, Kardell M, Joas E, Runeson B, Pålsson E, Landén M, "Characteristics of bipolar I and II disorder: a study of 8766 individuals," Bipolar Disorders 22(4), 2020, 392–400 — 4,806 bipolar I and 3,960 bipolar II; "BDII had higher rate of depressive episodes and more frequent suicide attempts than BDI… These results demonstrate clear differences between BDI and II and counter the notion that BDII is a milder form of BDI"; and "BDI patients had higher rate of hospitalizations and elated episodes, higher BMI, and higher rate of endocrine, nutritional, and metabolic diseases" — doi.org.
7. Dell'Osso B, Camuri G, Cremaschi L, et al., "Bipolar I and II disorders: a comparison of clinical and sociodemographic features," CNS Spectrums 22(4), 2017, 325–332 — bipolar II with more favourable occupational and marital circumstances alongside "significantly longer duration of untreated illness, more frequent lifetime anxiety disorders comorbidity" — doi.org.
8. US Food and Drug Administration, current prescribing information retrieved via the openFDA drug label API — LATUDA (lurasidone): "Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression)"; VRAYLAR (cariprazine): "Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adult patients"; olanzapine and fluoxetine capsules: "Acute depressive episodes in Bipolar I Disorder"; SEROQUEL XR (quetiapine): "The efficacy of SEROQUEL XR was established in one 8-week trial in adults with bipolar I or II disorder" — open.fda.gov.
9. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al., "The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders," American Journal of Psychiatry 170(11), 2013, 1249–1262 — "The frequency and severity of antidepressant-associated mood elevations appear to be greater in bipolar I than bipolar II disorder. Hence, in bipolar I patients antidepressants should be prescribed only as an adjunct to mood-stabilizing medications" — doi.org.
10. National Institute for Health and Care Excellence, "Bipolar disorder: assessment and management," clinical guideline CG185, recommendation 1.3.2 — "encourage people to invite a family member or carer to give a corroborative history" — nice.org.uk.
11. National Institute for Health and Care Excellence, clinical guideline CG185, recommendation 1.2.3 — "Do not use questionnaires in primary care to identify bipolar disorder in adults" — nice.org.uk.
12. Zimmerman M, Galione JN, Chelminski I, Young D, Dalrymple K, "Psychiatric diagnoses in patients who screen positive on the Mood Disorder Questionnaire," Psychiatry Research 185(3), 2011, 444–449 — "15.2% (n=65) of the 428 nonbipolar patients screened positive on MDQ" — doi.org.
13. Birmaher B, Axelson D, Goldstein B, et al., "Four-year longitudinal course of children and adolescents with bipolar spectrum disorders: the Course and Outcome of Bipolar Youth (COBY) study," American Journal of Psychiatry 166(7), 2009, 795–804 — "Twenty-five percent of youths with bipolar II converted to bipolar I" — pmc.ncbi.nlm.nih.gov.

Paid for by participating therapists. Inclusion is computed from availability data — never purchased. No ads, no data sold.